Aptose Biosciences (TSE:APS) Hits New 52-Week Low – Time to Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) shares hit a new 52-week low on Thursday . The company traded as low as C$0.50 and last traded at C$0.50, with a volume of 1500 shares changing hands. The stock had previously closed at C$0.49.

Aptose Biosciences Price Performance

The company has a market cap of C$9.96 million, a P/E ratio of -0.10 and a beta of 1.36. The company has a debt-to-equity ratio of 670.80, a current ratio of 0.80 and a quick ratio of 5.41. The company’s 50-day moving average price is C$0.54 and its 200-day moving average price is C$1.06.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported C($0.59) earnings per share for the quarter, topping the consensus estimate of C($0.80) by C$0.21. As a group, sell-side analysts predict that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.